Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HRH2 | P25021 | 3/20 | 0.55 |
| ▸ | HRH1 | P35367 | 3/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410113 | 0.92 | HRH3 (0.65) | LTA4HHRH3MAPTKDM4EALDH1A1 | |
| SCHEMBL26382840 | 0.91 | MEN1 (0.56) | LTA4HHRH3MAPTKDM4EALDH1A1 | |
| SCHEMBL16358244 | 0.89 | HRH3 (0.58) | HRH3KDM4EALDH1A1HRH2HRH1 | |
| SCHEMBL19462908 | 0.87 | LTA4H (0.64) | LTA4HHRH3MAPTKDM4EALDH1A1 | |
| SCHEMBL15834053 | 0.84 | HRH3 (0.66) | LTA4HHRH3KDM4E | |
| SCHEMBL8337754 | 0.84 | HRH3 (0.70) | LTA4HHRH3KDM4EALDH1A1 | |
| SCHEMBL13952170 | 0.84 | LTA4H (0.69) | LTA4HHRH3MAPTKDM4EALDH1A1 | |
| SCHEMBL3251652 | 0.83 | LTA4H (0.67) | LTA4HHRH3MAPTKDM4EALDH1A1 | |
| SCHEMBL12156443 | 0.83 | LTA4H (0.67) | LTA4HHRH3MAPTKDM4EALDH1A1 | |
| SCHEMBL10857813 | 0.83 | LTA4H (0.67) | LTA4HHRH3MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102924406-A | Substituted aryl oxygen ethylpiperazine derivative, preparation method of substituted aryl oxygen ethylpiperazine derivative and application of substituted aryl oxygen ethylpiperazine derivative | UNIV NANJING MEDICAL | 2013-02-13 | — | — | CN | claimed |
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-10-14 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| CN-110128369-A | Benzo [d] isothiazole -3 (2H) -one derivative and its preparation method and application | 东南大学 | 2019-08-16 | — | — | CN | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| CN-102924406-B | Substituted aryl oxygen ethylpiperazine derivative, preparation method of substituted aryl oxygen ethylpiperazine derivative and application of substituted aryl oxygen ethylpiperazine derivative | UNIV NANJING MEDICAL | 2014-11-05 | — | — | CN | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-5962453-A | HEPATITIS THERAPY | NIPPON SHINYAKU CO. LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| CN-1155244-A | Triazine derivative and medicine | NIPPON SHINYAKU CO LTD (JP) | 1997-07-23 | — | — | CN | disclosed |
| EP-0775487-A1 | TRIAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-05-28 | — | — | EP | disclosed |
| US-5147882-A | Cardiovascular disorders | KARL THOMAE GMBH (DE) | 1992-09-15 | — | — | US | disclosed |
| EP-0450429-A1 | Cyclophanes, process for their preparation and pharmaceuticals containing them | Dr. Karl Thomae GmbH (DE) | 1991-10-09 | — | — | EP | disclosed |
| CN-87100040-A | The alkylamine that alkyl diaryl replaces, its preparation technology's method, the medicine of using and containing this compounds | — | 1987-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | LTA4H 3562/4885HRH3 3690/4885MAPT 3617/4885 |
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | LTA4H 4652/4885HRH3 2940/4885MAPT 2288/4885 |
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | LTA4H 3948/4885HRH3 2108/4885MAPT 403/4885 |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | LTA4H 3777/4885HRH3 3355/4885MAPT 1271/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | LTA4H 3777/4885HRH3 3355/4885MAPT 1271/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | LTA4H 2580/4885HRH3 1946/4885MAPT 2558/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | LTA4H 2580/4885HRH3 1946/4885MAPT 2558/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | LTA4H 3562/4885HRH3 3690/4885MAPT 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.